Oligogenicity, C9orf72 expansion, and variant severity in ALS.


Journal

Neurogenetics
ISSN: 1364-6753
Titre abrégé: Neurogenetics
Pays: United States
ID NLM: 9709714

Informations de publication

Date de publication:
07 2020
Historique:
received: 17 01 2020
accepted: 04 04 2020
pubmed: 10 5 2020
medline: 16 6 2021
entrez: 10 5 2020
Statut: ppublish

Résumé

"Oligogenic inheritance" is used to describe cases where more than one rare pathogenic variant is observed in the same individual. While multiple variants can alter disease presentation, the necessity of multiple variants to instigate pathogenesis has not been addressed in amyotrophic lateral sclerosis (ALS). We sequenced ALS-associated genes in C9orf72-expansion-positive and negative ALS patients, alongside unaffected controls, to test the importance of oligogenicity and variant deleteriousness in ALS. We found that all groups had similar numbers of rare variants, but that variant severity was significantly higher in C9orf72-negative ALS cases, suggesting sufficiency of C9orf72 expansion to cause ALS alone.

Identifiants

pubmed: 32385536
doi: 10.1007/s10048-020-00612-7
pii: 10.1007/s10048-020-00612-7
doi:

Substances chimiques

C9orf72 Protein 0
C9orf72 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

227-242

Subventions

Organisme : CIHR
ID : FRN 159279
Pays : Canada

Auteurs

Jay P Ross (JP)

Department of Human Genetics, McGill University, Montréal, QC, Canada.
Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada.

Claire S Leblond (CS)

Human Genetics and Cognitive functions, Institut Pasteur, UMR 3571 CNRS, Sorbonne Paris Cité, University Paris Diderot, Paris, France.

Sandra B Laurent (SB)

Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada.
Department of Neurology and Neurosurgery, McGill University, Montréal, QC, H3A 2B4, Canada.

Dan Spiegelman (D)

Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada.
Department of Neurology and Neurosurgery, McGill University, Montréal, QC, H3A 2B4, Canada.

Alexandre Dionne-Laporte (A)

Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada.
Department of Neurology and Neurosurgery, McGill University, Montréal, QC, H3A 2B4, Canada.

William Camu (W)

Clinique du Motoneurone, Explorations neurologiques, CHU Gui de Chauliac, Université de Montpellier, Montpellier, France.

Nicolas Dupré (N)

Division of Neurosciences, CHU de Québec, Université Laval, Québec City, QC, Canada.
Department of Medicine, Faculty of Medicine, Université Laval, Québec City, QC, Canada.

Patrick A Dion (PA)

Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada.
Department of Neurology and Neurosurgery, McGill University, Montréal, QC, H3A 2B4, Canada.

Guy A Rouleau (GA)

Department of Human Genetics, McGill University, Montréal, QC, Canada. guy.rouleau@mcgill.ca.
Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada. guy.rouleau@mcgill.ca.
Department of Neurology and Neurosurgery, McGill University, Montréal, QC, H3A 2B4, Canada. guy.rouleau@mcgill.ca.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH